The major objective of this course is to provide a detailed insight into the practical aspects and approaches of process scale-up for different unit operations and technologies.
The 9th Project and Portfolio Management for Pharma & Biotech East or West – Learn from the best
In a time when pharma R&D costs are increasing and mergers & acquisitions are at an all-time high, the industry needs to consider its next steps.
Learn both practice and the art of research plus summarize the latest insights from both industry professionals and strategic decision makers. Portfolio management can be whatever senior management makes of it. It involves a broad mix containing everything from strategic management, decision making, risk evaluation and innovative thinking through different portfolio and product strategies to navigating between regulatory issues and market demands.
Do you want to learn:
· How disruptive projects are different?
· Why to launch them and how to manage them?
· How to achieve rewards?
· How to manage risk at the portfolio level?
· How to balance costs and new drug approvals?
· How to innovate in R&D?
Join The 9th Project and Portfolio Management for Pharma and Biotech – East, 9th - 10th March 2016, in Philadelphia. Are you busy during these dates or do you live closer to the west coast area?
Then join The 9th Project and Portfolio Management for Pharma and Biotech – West held 11th - 12th April 2016 in San Francisco.
Bringing together senior executives from pharma and biotech, these events seek to explore new advancements in portfolio management. Professionals from companies such as Eli Lilly and Company, Johnson & Johnson Innovation, Pfizer, AstraZeneca, Novartis and Allergan are on board.
How will you learn?
· CEO roundtable
· Interactive platform
· Point-of-View session hosted by industry leaders
· Real-world case studies
· Practical exercises
Over 10 hours of knowledge sharing and 8 hours of networking over coffee, lunch and cocktails make these events not to be missed.
Interested in this topic?
Targeted Drug Delivery
Gain detailed overview of the newest strategies in drug delivery and targeting.
Next Generation Antibody Therapeutics
This focused 2-day training will cover the discovery, engineering and production of next-generation antibodies, antibody fragments, bispecific Abs, innovative ADCs and more. Follow the path from their discovery and selection through engineering and expression to production and regulatory issues.
White Paper: Beyond the Cold Chain
Take a Good Look at the Future of Corporate Universities
There are four things corporate universities can do to avoid becoming irrelevant in the digital age.
Ready for the new GCP ICH E6 (R2) addendum?
On the 23rd of July 2015, the EMA's Committee for Human Medicinal Products released the Guideline for Good Clinical Practice E6(R2) for consultation. On the 14th of June 2017, it will come into effect and influence everyone involved in the clinical research process. What does it mean to pharma and biotech companies, sponsors, CROs, research institutes and third-party organizations?